Qube Research & Technologies (QRT)’s Bicara Therapeutics BCAX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.93M	Buy	+210,933	New	+$5.28M	﹤0.01%	1950

Other funds holding BCAX

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JHC

Jones Hill Capital New York $589M AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BCAX Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 210,933 shares worth $3.93M. The stake represents ﹤0.01% of the portfolio and ranks #1950 among its holdings.

114 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

Qube Research & Technologies (QRT) held 210,933 shares of Bicara Therapeutics worth $3.93M as of Q3 2026.
Bicara Therapeutics was a new Qube Research & Technologies (QRT) position in Q3 2026.
Bicara Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #1950 holding.
114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.